Clinical development, from First in human to Phase 3 registrational studies

The CALYM consortium of international KOLs provides expertise in lymphoma and multiple myeloma for clinical development, from synopsis to study conduct (from first-in-human to registrational Phase 3). It includes : LYSA, gathering 500 lymphoma specialists through 90 centers in 3 countries, collaborating internationally, and the LYSARC, the largest CRO in Europe dedicated to lymphoma; IFM, gathering 140 French and 33 Belgian centers around research on MM, which already conducted to new international standard of care.